Literature DB >> 32684864

Label-free quantitative mass spectrometry from formalin-fixed paraffin-embedded samples of nasopharyngeal carcinoma: Preliminary results from a non-endemic European cohort of patients.

Eduardo Netto1,2, Hugo Santos3,4, Luís Carvalho3,4, José Luis Capelo-Martínez3,4, Miguel Rito5, José Cabeçadas5, Margarida Roldão1,2.   

Abstract

AIM: Report our results of biomarker discovery in formalin-fixed paraffin-embedded (FFPE) nasopharyngeal carcinoma (NPC) via proteomic analysis.
BACKGROUND: Nasopharyngeal carcinoma (NPC) is a rare cancer in Western countries. Proteomic analysis have already been reported as a useful tool to provide biomarkers. Formalin-fixed paraffin-embedded (FFPE) samples, despite largely underused, can provide invaluable information for biomarker research via proteomic analysis.
METHODS: FFPE samples of NPC were submitted to protein extraction followed by FASP-digestion and label-free quantitative mass spectrometry (MS). Patients' received concurrent chemoradiation with or without adjuvant chemotherapy as per Intergroup 0099 trial. IMRT was delivered following the RTOG0615 specifications. Toxicity was scored using the CTCAE 4.03 tables. Survival was estimated using Kaplan-Meier curves. Log-rank was used to detect differences. KEGG ontology graphics were generated.
RESULTS: 28 FFPE samples from NPC patients were used. Patients were: 79% male, 97% Caucasians, 86% WHO type 3, 40% T1, 10% T2, 25% T3, and 25% T4. With a median follow up of 37 months, local control was 83 (T1, 100% T2, T3 and T4), overall survival was 84%, and six patients developed distant metastases. All five patients that died were due to metastatic disease. Tumor samples contained a median of 75% of tumor material. We found Epstein-Barr (EBV) and Herpes simplex (HSV) viruses' related proteins significantly present in early-stage primary NPC (T1 and T2, p < 0.01). A pool of 10 proteins was statistically up-regulated in the metastatic group of patients (p < 0.01). Median survival from this M1 group was <1 year (p < 0.001).
CONCLUSIONS: FFPE samples yielded adequate material for MS analysis. We found EBV and HSV related proteins on early-stage NPC, and proteomic profiling associated with distant metastases, potential candidates of disease biomarkers. Validation is needed.
© 2020 Greater Poland Cancer Centre. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Biomarkers; Metastases prediction; Nasopharyngeal carcinoma; Proteomic analysis

Year:  2020        PMID: 32684864      PMCID: PMC7358631          DOI: 10.1016/j.rpor.2020.05.007

Source DB:  PubMed          Journal:  Rep Pract Oncol Radiother        ISSN: 1507-1367


  29 in total

1.  Modulation of LMP1 protein expression by EBV-encoded microRNAs.

Authors:  Angela Kwok Fung Lo; Ka Fai To; Kwok Wai Lo; Raymond Wai Ming Lung; Jan Wai Ying Hui; Gangling Liao; S Diane Hayward
Journal:  Proc Natl Acad Sci U S A       Date:  2007-10-02       Impact factor: 11.205

2.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification.

Authors:  Jürgen Cox; Matthias Mann
Journal:  Nat Biotechnol       Date:  2008-11-30       Impact factor: 54.908

3.  Nasopharyngeal cancer: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Authors:  A T C Chan; V Grégoire; J-L Lefebvre; L Licitra; E P Hui; S F Leung; E Felip
Journal:  Ann Oncol       Date:  2012-10       Impact factor: 32.976

4.  Surrogate End Points for Overall Survival in Loco-Regionally Advanced Nasopharyngeal Carcinoma: An Individual Patient Data Meta-analysis.

Authors:  Federico Rotolo; Jean-Pierre Pignon; Jean Bourhis; Sophie Marguet; Julie Leclercq; Wai Tong Ng; Jun Ma; Anthony T C Chan; Pei-Yu Huang; Guopei Zhu; Daniel T T Chua; Yong Chen; Hai-Qiang Mai; Dora L W Kwong; Yoke Lim Soong; James Moon; Yuk Tung; Kwan-Hwa Chi; George Fountzilas; Li Zhang; Edwin Pun Hui; Anne W M Lee; Pierre Blanchard; Stefan Michiels
Journal:  J Natl Cancer Inst       Date:  2017-04       Impact factor: 13.506

5.  Novel biomarkers of nasopharyngeal carcinoma metastasis risk identified by reverse phase protein array based tumor profiling with consideration of plasma Epstein-Barr virus DNA load.

Authors:  Tao Xu; Bojin Su; Peiyu Huang; Weihong Wei; Yanming Deng; Vasudha Sehgal; Donghui Wang; Jun Jiang; Guoyi Zhang; Anfei Li; Huiling Yang; Francois X Claret
Journal:  Proteomics Clin Appl       Date:  2016-12-29       Impact factor: 3.494

6.  Addition of bevacizumab to standard chemoradiation for locoregionally advanced nasopharyngeal carcinoma (RTOG 0615): a phase 2 multi-institutional trial.

Authors:  Nancy Y Lee; Qiang Zhang; David G Pfister; John Kim; Adam S Garden; James Mechalakos; Kenneth Hu; Quynh T Le; A Dimitrios Colevas; Bonnie S Glisson; Anthony Tc Chan; K Kian Ang
Journal:  Lancet Oncol       Date:  2011-12-15       Impact factor: 41.316

7.  Nonendemic HPV-positive nasopharyngeal carcinoma: association with poor prognosis.

Authors:  Matthew H Stenmark; Jonathan B McHugh; Matthew Schipper; Heather M Walline; Christine Komarck; Felix Y Feng; Francis P Worden; Gregory T Wolf; Douglas B Chepeha; Mark E Prince; Carol R Bradford; Suresh K Mukherji; Avraham Eisbruch; Thomas E Carey
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-03-01       Impact factor: 7.038

8.  Accessing microenvironment compartments in formalin-fixed paraffin-embedded tissues by protein expression analysis.

Authors:  Fabrizio Donnarumma; Ákos Végvári; Melinda Rezeli; Charlotte Welinder; Bo Jansson; György Marko-Varga
Journal:  Bioanalysis       Date:  2013-11       Impact factor: 2.681

9.  Immunoassay for LMP1 in nasopharyngeal tissue based on surface-enhanced Raman scattering.

Authors:  Yanping Chen; Xiongwei Zheng; Gang Chen; Chen He; Weifeng Zhu; Shangyuan Feng; Gangqin Xi; Rong Chen; Fenghua Lan; Haishan Zeng
Journal:  Int J Nanomedicine       Date:  2011-12-30

10.  Reduced RKIP enhances nasopharyngeal carcinoma radioresistance by increasing ERK and AKT activity.

Authors:  Li Yuan; Hong-Mei Yi; Hong Yi; Jia-Quan Qu; Jin-Feng Zhu; Li-Na Li; Ta Xiao; Zhen Zheng; Shan-Shan Lu; Zhi-Qiang Xiao
Journal:  Oncotarget       Date:  2016-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.